Related Experiment Video
Updated: May 13, 2026
The Intra-Aortic Balloon Pump
Published on: February 5, 2021
[Farewell to the intra-aortic balloon pump?]
José P S Henriques1, Bas A J M de Mol
1Academisch Medisch Centrum, AMC Hartcentrum, Amsterdam, the Netherlands. j.p.henriques@amc.uva.nl
Insights
The intra-aortic balloon pump (IABP), used for decades in cardiac care, is becoming obsolete due to recent trial failures. Future cardiac devices require rigorous testing before widespread clinical use.
Area of Science:
- Cardiovascular Medicine
- Medical Device Technology
- Clinical Trials
Context:
- The intra-aortic balloon pump (IABP) has been a mainstay in cardiac procedures for over 50 years.
- It has been primarily utilized for acute myocardial infarction and cardiogenic shock.
- Recent clinical trial data has questioned its efficacy, particularly in cardiogenic shock.
Purpose:
- To critically evaluate the historical role and future of the intra-aortic balloon pump (IABP).
- To discuss the implications of recent clinical trial outcomes on IABP usage.
- To emphasize the importance of robust clinical evidence for new medical technologies.
Summary:
- The intra-aortic balloon pump (IABP), a long-standing device in cardiology and cardiothoracic surgery, faces a significant decline in clinical use.
- Its failure to demonstrate efficacy in recent cardiogenic shock trials suggests its role will become extremely limited.
- The experience with IABP highlights the need to avoid reliance on surrogate endpoints and prioritize randomized controlled trials.
Impact:
- This analysis signals a potential paradigm shift in mechanical circulatory support for acute cardiac conditions.
- It underscores the critical need for evidence-based medicine and rigorous evaluation of medical devices.
- Future development and adoption of cardiac support technologies must be guided by high-quality clinical evidence from randomized controlled trials.
Abstract:
The intra-aortic balloon pump (IABP) has been a reliable friend in the catheterization laboratory and operating room. This good old friend of the cardiologist and cardiothoracic surgeon is about to disappear from the clinical scene. For more than 5 decades, it has largely been deployed for acute myocardial infarction and cardiogenic shock. Its more recent failure to demonstrate efficacy for cardiogenic shock will herald its demise. It may not disappear completely but its usage will become extremely limited. The lesson we have learned from the IABP history and other therapies is that we should never trust surrogate endpoints such as cardiac (power) output when it comes to cardiogenic shock. Newer devices should be tested in properly randomized controlled clinical trials before worldwide adoption.
